Checkmate 142 is an ongoing clinical trial (NCT02060188) investigating nivolumab in MSI-H metastatic or recurrent CRC, in combination with other checkpoint inhibitors with targets other than the PD-1/PD-L1 axis. This evidence concerns the gene CD274 and colorectal carcinoma.